2020
Validating a non-invasive, ALT-based non-alcoholic fatty liver phenotype in the million veteran program
Serper M, Vujkovic M, Kaplan DE, Carr RM, Lee KM, Shao Q, Miller DR, Reaven PD, Phillips LS, O’Donnell C, Meigs JB, Wilson PWF, Vickers-Smith R, Kranzler HR, Justice AC, Gaziano JM, Muralidhar S, Pyarajan S, DuVall SL, Assimes TL, Lee JS, Tsao PS, Rader DJ, Damrauer SM, Lynch JA, Saleheen D, Voight BF, Chang KM, . Validating a non-invasive, ALT-based non-alcoholic fatty liver phenotype in the million veteran program. PLOS ONE 2020, 15: e0237430. PMID: 32841307, PMCID: PMC7447043, DOI: 10.1371/journal.pone.0237430.Peer-Reviewed Original ResearchMeSH Keywords17-Hydroxysteroid DehydrogenasesAbdomenAdaptor Proteins, Signal TransducingAgedAlanine TransaminaseElectronic Health RecordsFemaleGenetic LociGenetic Predisposition to DiseaseGenetic VariationHumansLipaseLiverLysophospholipaseMaleMembrane ProteinsMiddle AgedNon-alcoholic Fatty Liver DiseasePhenotypeRisk FactorsVeteransConceptsMetabolic risk factorsNAFLD phenotypeAlanine aminotransferaseUnits/LElectronic health recordsAdvanced fibrosisRisk factorsMillion Veteran ProgramAlcohol consumptionNon-invasive criteriaNormal alanine aminotransferaseNAFLD fibrosis scorePopulation-based studyGenetic variantsFatty liver phenotypeVeteran ProgramPNPLA3 locusNAFLD riskLiver biopsyLiver diseaseFibrosis scoreEHR reviewUS veteransBiopsy dataAbdominal imagingDifferences in Pathology, Staging, and Treatment between HIV+ and Uninfected Patients with Microscopically Confirmed Hepatocellular Carcinoma
Torgersen J, Taddei TH, Park LS, Carbonari DM, Kallan MJ, Richards K, Zhang X, Jhala D, Bräu N, Homer R, D'Addeo K, Mehta R, Skanderson M, Kidwai-Khan F, Justice AC, Re V. Differences in Pathology, Staging, and Treatment between HIV+ and Uninfected Patients with Microscopically Confirmed Hepatocellular Carcinoma. Cancer Epidemiology Biomarkers & Prevention 2020, 29: 71-78. PMID: 31575557, PMCID: PMC6980754, DOI: 10.1158/1055-9965.epi-19-0503.Peer-Reviewed Original ResearchMeSH KeywordsAblation TechniquesCarcinoma, HepatocellularFemaleHepatectomyHIV InfectionsHospitals, VeteransHumansImmunologic SurveillanceKaplan-Meier EstimateLiverLiver CirrhosisLiver NeoplasmsLiver TransplantationMaleMiddle AgedNeoplasm StagingRetrospective StudiesRisk FactorsTreatment OutcomeUnited StatesConceptsBarcelona Clinic Liver Cancer stageHIV statusHepatocellular carcinomaUninfected patientsHIV infectionTumor characteristicsUninfected personsPathology reportsVeterans Aging Cohort StudyLiver tissue samplingCohort of HIVMultivariable Cox regressionAdvanced hepatic fibrosisAging Cohort StudyLiver Cancer stageRisk of deathBackground hepatic parenchymaCohort studyHazard ratioLymphovascular invasionBCLC stageImproved survivalCox regressionHistologic featuresHepatic fibrosis
2017
Risk of liver decompensation with cumulative use of mitochondrial toxic nucleoside analogues in HIV/hepatitis C virus coinfection
Re V, Zeldow B, Kallan MJ, Tate JP, Carbonari DM, Hennessy S, Kostman JR, Lim JK, Goetz MB, Gross R, Justice AC, Roy JA. Risk of liver decompensation with cumulative use of mitochondrial toxic nucleoside analogues in HIV/hepatitis C virus coinfection. Pharmacoepidemiology And Drug Safety 2017, 26: 1172-1181. PMID: 28722244, PMCID: PMC5624832, DOI: 10.1002/pds.4258.Peer-Reviewed Original ResearchConceptsHepatitis C virusHIV/HCV patientsHuman immunodeficiency virusHepatic decompensationAntiretroviral therapyHCV patientsCohort studyHazard ratioHIV/hepatitis C virus (HCV) coinfectionChronic hepatitis C virusHepatitis C virus coinfectionHIV/HCV coinfectionHIV-/HCV-coinfected patientsVeterans Aging Cohort StudyC virus coinfectionChronic hepatic injuryAging Cohort StudyRisk of deathToxic nucleoside analoguesMarginal structural modelsHCV coinfectionLiver decompensationART regimensDecompensation eventsHepatic injury
2011
Hepatic Safety and Antiretroviral Effectiveness in HIV‐Infected Patients Receiving Naltrexone
Tetrault JM, Tate JP, McGinnis KA, Goulet JL, Sullivan LE, Bryant K, Justice AC, Fiellin DA, Team F. Hepatic Safety and Antiretroviral Effectiveness in HIV‐Infected Patients Receiving Naltrexone. Alcohol Clinical And Experimental Research 2011, 36: 318-324. PMID: 21797892, PMCID: PMC3221963, DOI: 10.1111/j.1530-0277.2011.01601.x.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAlanine TransaminaseAlcoholismAntiretroviral Therapy, Highly ActiveAspartate AminotransferasesCD4 Lymphocyte CountChemical and Drug Induced Liver InjuryCohort StudiesDatabases, FactualDrug InteractionsDrug-Related Side Effects and Adverse ReactionsFemaleHIV InfectionsHumansLiverLiver Function TestsMaleMiddle AgedNaltrexoneNarcotic AntagonistsOpioid-Related DisordersRNA, ViralVeteransConceptsNaltrexone prescriptionAlanine aminotransferaseOpioid dependenceVeterans Aging Cohort Study Virtual CohortAspartate aminotransferaseImpact of naltrexoneSignificant alanine aminotransferaseLiver enzyme elevationMean CD4 countHIV-infected individualsAST changesHepatic safetyHIV biomarkersOral naltrexoneCD4 countHIV RNAMedian durationEnzyme elevationMedian ageAST levelsNaltrexone useHepatic enzymesAntiretroviral effectivenessHIVPatients